 |
Top 11 Ovarian Cancer treatment startups
Oct 12, 2024 | By Jason Kwon | 15 |
These startups develop new ovarian cancer treatments and diagnostics technologies, such as medical imaging AI, robotic laparoscopy, targeted therapy, immunotherapy, smart chemotherapy, liquid biopsy.
1
Country: Denmark | Funding: $114.6M
ADCendo is dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the ADC approach to new levels through a focus on cancer-associated targets that are professional internalizers and allow for superior selectivity via highly preferential cancer expression.
ADCendo is dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the ADC approach to new levels through a focus on cancer-associated targets that are professional internalizers and allow for superior selectivity via highly preferential cancer expression.
2
Country: UK | Funding: $50M
Enara Bio offers targeted cancer immunotherapies. It is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
Enara Bio offers targeted cancer immunotherapies. It is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
3
Country: USA | Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
4
Country: USA | Funding: $278.1M
InterVenn Biosciences combined the molecular-level resolution of mass spectrometry with the throughput of artificial intelligence to create a unique platform to discover new biomarkers, provide more effective treatments, design precision medicine trials, and pursue novel targets.
InterVenn Biosciences combined the molecular-level resolution of mass spectrometry with the throughput of artificial intelligence to create a unique platform to discover new biomarkers, provide more effective treatments, design precision medicine trials, and pursue novel targets.
5
Country: USA | Funding: $156M
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
6
Country: UK | Funding: $52M
Iksuda Therapeutics is a biotechnology company specializing in the development of next generation biotherapeutics
Iksuda Therapeutics is a biotechnology company specializing in the development of next generation biotherapeutics
7
Country: USA | Funding: $18.8M
4D Path uses H&E biopsy images to unveil hidden data instantly providing biomarker profiling and stratification. Although their initial focus is on breast cancer, the company is actively working on developing products for ovarian cancer, cervical cytology, skin cancer, and, in general, around immunotherapy in various cancers.
4D Path uses H&E biopsy images to unveil hidden data instantly providing biomarker profiling and stratification. Although their initial focus is on breast cancer, the company is actively working on developing products for ovarian cancer, cervical cytology, skin cancer, and, in general, around immunotherapy in various cancers.
8
Country: USA | Funding: $15.7M
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology.
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology.
9
Country: USA | Funding: $9.9M
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma and ovarian cancer.
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma and ovarian cancer.
10
Country: USA | Funding: $120K
Tradewind BioScience is a biotechnology company developing antibody therapeutics for ovarian cancer.
Tradewind BioScience is a biotechnology company developing antibody therapeutics for ovarian cancer.
